Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16130614 | 0.94 | SMN1; SMN2 (0.36) | PSMB8PSMB5KMT2ASMN1; SMN2ALOX12 | |
| SCHEMBL7877323 | 0.93 | SMN1; SMN2 (0.38) | PSMB8PSMB5KMT2ASMN1; SMN2PRKCA | |
| SCHEMBL16303081 | 0.93 | SMN1; SMN2 (0.38) | PSMB8PSMB5KMT2ASMN1; SMN2PRKCA | |
| Ethylene Glycol SCHEMBL6523939 | 0.92 | PSMB8 (0.34) | PSMB8PSMB5KMT2ASMN1; SMN2ALOX12 | |
| SCHEMBL290461 | 0.90 | SMN1; SMN2 (0.40) | PSMB8PSMB5KMT2ASMN1; SMN2ALOX12 | |
| SCHEMBL22777675 | 0.90 | SMN1; SMN2 (0.36) | PSMB8PSMB5KMT2ASMN1; SMN2ALOX12 | |
| SCHEMBL34383 | 0.90 | SMN1; SMN2 (0.36) | PSMB8PSMB5KMT2ASMN1; SMN2ALOX12 | |
| SCHEMBL12410445 | 0.90 | PSMB8 (0.32) | PSMB8PSMB5MGLL | |
| SCHEMBL905722 | 0.88 | SMN1; SMN2 (0.42) | PSMB8PSMB5KMT2ASMN1; SMN2ALOX12 | |
| SCHEMBL905700 | 0.88 | SMN1; SMN2 (0.42) | PSMB8PSMB5KMT2ASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110282464-A1 | Reactive Surgical Implants | SOFRADIM PRODUCTION (FR) | 2011-11-17 | — | — | US | claimed |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2023-09-28 | — | — | US | disclosed |
| WO-2023114833-A9 | DOSING REGIMENS FOR SELECTIVE TREG STIMULATOR RUR20KD-IL-2 AND RELATED COMPOSITIONS | NEKTAR THERAPEUTICS (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | APELLIS PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023114833-A1 | DOSING REGIMENS FOR SELECTIVE TREG STIMULATOR RUR20KD-IL-2 AND RELATED COMPOSITIONS | ELI LILLY AND COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20210205413-A1 | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS | NEKTAR THERAPEUTICS | 2021-07-08 | — | — | US | disclosed |
| EP-3796940-A1 | SELECTIVE TREG STIMULATOR RUR20KD-IL-2 AND RELATED COMPOSITIONS | Nektar Therapeutics (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3641801-A1 | MODIFIED MEMBRANE TYPE SERINE PROTEASE 1 (MTSP-1) POLYPEPTIDES AND METHODS OF USE | Catalyst Biosciences, Inc. (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2018237201-A1 | MODIFIED MEMBRANE TYPE SERINE PROTEASE 1 (MTSP-1) POLYPEPTIDES AND METHODS OF USE | CATALYST BIOSCIENCES, INC. (US) | 2018-12-27 | — | — | WO | disclosed |
| EP-2444075-B1 | Self-supporting films for delivery of therapeutic agents | COVIDIEN LP (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20070288052-A1 | In situ materials formation | INCEPT LLC | 2007-12-13 | — | — | US | disclosed |
| WO-2007127473-A2 | POLY (ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1105180-A4 | METHODS AND APPARATUS FOR INTRALUMINAL DEPOSITION OF HYDROGELS | INCEPT LLC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7220270-B2 | Methods and apparatus for intraluminal deposition of hydrogels | INCEPT LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-20050080445-A1 | Methods and apparatus for intraluminal deposition of hydrogels | INCEPT LLC | 2005-04-14 | — | — | US | disclosed |
| US-6689148-B2 | Methods and apparatus for intraluminal deposition of hydrogels | INCEPT LLC | 2004-02-10 | — | — | US | disclosed |
| US-20020082636-A1 | Methods and apparatus for intraluminal deposition of hydrogels | INCEPT LLC | 2002-06-27 | — | — | US | disclosed |
| US-6379373-B1 | Methods and apparatus for intraluminal deposition of hydrogels | CONFLUENT SURGICAL, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1105180-A1 | METHODS AND APPARATUS FOR INTRALUMINAL DEPOSITION OF HYDROGELS | INCEPT LLC (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000009190-A1 | METHODS AND APPARATUS FOR INTRALUMINAL DEPOSITION OF HYDROGELS | INCEPT LLC (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282464-A1 | Reactive Surgical Implants | CYBB, F2RL3, MACF1 | PSMB8 461/4885PSMB5 1102/4885KMT2A 2301/4885 |
| US-20210205413-A1 | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS | IL2, IL2RA, ICOS | PSMB8 2873/4885PSMB5 3658/4885KMT2A 2080/4885 |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SNRPE, RNASE1, SNRPF | PSMB8 936/4885PSMB5 1114/4885KMT2A 3213/4885 |
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | C5, C3AR1, C1QBP | PSMB8 1815/4885PSMB5 528/4885KMT2A 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.